Meeting
2011 Genitourinary Cancers Symposium
Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Xuan Huang
Medical Oncology Branch, National Cancer Institute
Xuan Huang , James Gulley , Paul Kluetz , Ravi Madan , William Figg , William Dahut
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCI 8217
Citation
J Clin Oncol 29: 2011 (suppl 7; abstr 138)
Abstract #
138
Poster Bd #
A32
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: X. Huang
Poster
2012 ASCO Annual Meeting
Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Bamidele Adesunloye
Poster
2015 Genitourinary Cancers Symposium
Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results.
First Author: Joaquin Mateo
Poster
2014 ASCO Annual Meeting
A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).
First Author: Daniel Louis Hertz